“GSK Expands Respiratory Portfolio with Aiolos Bio Acquisition”

GSK Acquires Aiolos Bio: Expanding Respiratory Treatment Options

GSK plc (LSE/NYSE: GSK) has recently announced its acquisition of Aiolos Bio, Inc., a clinical-stage biopharmaceutical company, in a deal worth $1 billion. This strategic move aims to bolster GSK’s respiratory treatment options by adding AIO-001, a long-acting antibody that targets the TSLP pathway. This pathway is implicated in various respiratory and inflammatory conditions. By acquiring Aiolos Bio, GSK intends to enhance its portfolio and address the unmet needs of patients suffering from respiratory diseases.